All In Biotech

NDA 018057 · Hq Spclt Pharma

Platinol-Aq

Cisplatin · Injection · Platinum-based Drug

Novel

Last checked: Nov 20, 2026Latest source record: Mar 24, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1978

Dec 19, 1978

Approved uses

3

Original approval plus efficacy supplements

Registered trials

4,792

1,209 Phase 3, 731 recruiting

FAERS reports

79,029

76,537 serious, 15,097 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY, NAUSEA AND VOMITING and MYELOSUPPRESSION. • Nephrotoxicity: cisplatin for injection can cause severe renal toxicity, including acute renal failure. Severe renal toxicities are dose-related and cumulative. Ensure adequate hydration and monitor renal function and electrolytes. Consider dose reductions or alternative treatments in patients with renal impairment [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 )]. • Peripheral Neuropathy: cisplatin for injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug [see Warnings and Precautions ( 5.2 )]. • Nausea and Vomiting: cisplatin for injection can cause severe nausea and vomiting. Use highly effective antiemetic premedication [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.3 )]. •...

What it is approved for

From the label in effect Jun 24, 2026.

Cisplatin for injection is a platinum-based drug indicated for the treatment of: • Advanced testicular cancer ( 1.1 ) • Advanced ovarian cancer ( 1.2 ) • Advanced bladder cancer ( 1.3 ) 1.1 Advanced Testicular Cancer Cisplatin for injection is indicated for the treatment of advanced testicular cancer. 1.2 Advanced Ovarian Cancer Cisplatin for injection is indicated for the treatment of advanced ovarian cancer. 1.3 Advanced Bladder Cancer Cisplatin for injection is indicated for the treatment of advanced bladder cancer.

Mechanism: The main mechanism of the cytotoxic action involves the binding of cisplatin to genomic DNA in the cell nucleus to form interstrand and intrastrand cross-links. This interferes with normal transcription and/or DNA replication mechanisms and triggers cytotoxic processes that lead to cell death.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 22, 1993 Supplement 61 · Efficacy
  • Dec 29, 1981 Supplement 12 · Efficacy
  • Dec 19, 1978 Original approval · Type 1 - New Molecular Entity
4 products under this application
  • PLATINOL-AQ · CISPLATIN 0.5MG/ML · INJECTABLE, INJECTION · Discontinued
  • PLATINOL · CISPLATIN 10MG/VIAL · INJECTABLE, INJECTION · Discontinued
  • CISPLATIN · CISPLATIN 1MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • CISPLATIN · CISPLATIN 50MG/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cisplatin" as an intervention, any sponsor and status, largest first.

All 4,792 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use6,031
  • nausea5,501
  • neutropenia4,930
  • disease progression4,706
  • febrile neutropenia4,684
  • vomiting4,613
  • anaemia4,126
  • thrombocytopenia3,876
  • diarrhoea3,799
  • pyrexia3,439
  • malignant neoplasm progression3,368
  • drug ineffective3,357

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,414
20051,699
20061,337
20071,579
20081,737
20091,914
20102,315
20112,826
20123,162
20132,276
20142,448
20153,410
20163,449
20173,770
20184,188
20194,520
20204,573
20214,631
20225,374
20236,288
20246,187
20255,818
20264,111

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cisplatin (Cisplatin)

2024 spending

$37K

Beneficiaries

249

764 claims

Per beneficiary

$147

$0.30 per unit

View as table
YearSpending
2020$22,492
2021$29,248
2022$37,713
2023$26,093
2024$36,667

Part B: Cisplatin (Cisplatin) · HCPCS J9060

2024 spending

$720K

Beneficiaries

6,086

28,889 claims

Per beneficiary

$118

2024 ASP limit $3.36 per unit

View as table
YearSpending
2020$514,430
2021$461,567
2022$480,444
2023$519,417
2024$719,809

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 11,471 on PubMed

Sponsor: Hq Spclt Pharma · Also marketed as Platinol, Cisplatin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.